Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch & Lomb CorpBLCO · Entity 3756 | Director · CEO & Chairman | May 05, 2022 | May 09, 2022 |
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | May 10, 2022 | May 13, 2022 |
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | September 30, 2026 | October 02, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director · President and CEO | April 29, 2026 | May 01, 2026 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch & Lomb Corp
Report date May 05, 2022 · Filed May 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 472,222 |
Reported balance
After 2022-05-05 transaction · row 1
1 source rowRow 1 · 2022-05-05 · Grant · Acquired 472,222 · Balance 472,222 F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation. |
| Non-Qualified Stock Options (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 | Direct | 1,868,131 |
Reported balance
After 2022-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-05 · Grant · Acquired 1,868,131 · Balance 1,868,131 F2: Reflects the grant of stock options to purchase Common Shares under the Plan. F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4: The stock options will expire on the tenth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.
F2: Reflects the grant of stock options to purchase Common Shares under the Plan.
F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.
F4: The stock options will expire on the tenth anniversary of the grant date.
Bausch Health Companies Inc.
Report date May 10, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 1,427,568 |
Ending reported balance
After 2022-05-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-05-10 · Exercise / conversion · Acquired 116,697 · Balance 1,211,849 F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F4: Each PSU converts into Common Shares on a one-for-one basis. Row 2 · 2022-05-10 · Exercise / conversion · Acquired 183,522 · Balance 1,395,371 F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F4: Each PSU converts into Common Shares on a one-for-one basis. Row 3 · 2022-05-10 · Exercise / conversion · Acquired 65,911 · Balance 1,461,282 F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. F4: Each PSU converts into Common Shares on a one-for-one basis. Row 4 · 2022-05-10 · Tax withholding · Disposed 33,714 · Balance 1,427,568 F5: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of the reporting person's Separation PSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-10 · Grant · Acquired 116,697 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-10 · Exercise / conversion · Disposed 116,697 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-10 · Grant · Acquired 183,522 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-10 · Exercise / conversion · Disposed 183,522 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-10 · Grant · Acquired 65,911 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-05-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-10 · Exercise / conversion · Disposed 65,911 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service.
F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service.
F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer.
F4: Each PSU converts into Common Shares on a one-for-one basis.
F5: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of the reporting person's Separation PSUs.
Candel Therapeutics, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2036-09-30 | Direct | 1,325 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 1,325 · Balance 1,325 F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
Emergent BioSolutions Inc.
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 493,153 |
Reported balance
After 2026-04-29 transaction · row 1
1 source rowRow 1 · 2026-04-29 · Grant · Acquired 187,708 · Balance 493,153 F1: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.
F2: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Milestone Pharmaceuticals Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10 | Direct | 77,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Prometheus Biosciences, Inc.
Report date June 16, 2023 · Filed June 16, 2023
Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Disposition to issuer · Disposed 7,278 · Balance 0 F1: Includes 2,278 restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Common StockSEC Table I · non-derivative | IndirectBy The Papa Family Charitable Trust | 0 |
Reported balance
After 2023-06-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-06-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F4: The Reporting Person is a Trustee to The Papa Family Charitable Trust. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2030-08-24 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2030-12-17 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-16 · Disposition to issuer · Disposed 27,340 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-16 · Disposition to issuer · Disposed 22,652 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.32 · Expires 2031-11-13 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-16 · Disposition to issuer · Disposed 2,165 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-16 · Disposition to issuer · Disposed 22,551 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,278 restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)
F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
F4: The Reporting Person is a Trustee to The Papa Family Charitable Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 5,115 | $24.06 | $123,066.90 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 5 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,795 F6 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 208,231 | $24.35 Strike: $24.35 | $5,070,424.85 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · derivative · entry 7 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantRestricted Share Units · Derivative | 208,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · derivative · entry 6 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 208,231 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 13,206 | $24.35 | $321,566.10 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 4 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,910 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 100,351 | $24.35 | $2,443,546.85 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139,299 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 208,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 13,183 | $24.35 | $321,006.05 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,116 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| November 14, 2021 Filed Nov 17, 2021 02:15 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 2,165 | $0.00 Strike: $36.32 | $0.00 |
DisclosureSEC source: 0001209191-21-064939 · doc4.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,165 Underlying: Common Stock · 2,165 shares Expires 2031-11-13 F1 · derivative.exercise_date: The shares subject to the option will vest on the first anniversary of the vesting commencement date measured from November 14, 2021, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 21:15 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 5,010 | $28.66 | $143,586.60 |
DisclosureSEC source: 0001127602-21-025347 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,419 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:15 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 3,549 | $29.19 | $103,595.31 |
DisclosureSEC source: 0001127602-21-025347 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,429 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 01:48 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | PurchaseCommon Stock | 15,000 | $19.00 | $285,000.00 |
DisclosureSEC source: 0001209191-21-021218 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 02:01 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 231,188 | $32.97 | $7,622,268.36 |
DisclosureSEC source: 0001127602-21-010168 · form4.xml · nonDerivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,039,978 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs and RSUs. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 02:01 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 317,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010168 · form4.xml · derivative · entry 4 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 317,089 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. F4 · derivative.exercise_date: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F4 · derivative.expiration_date: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on March 9, 2018 with the maximum potential award amount of 511,434 shares. Any portion of the award not vested as of the transaction date was cancelled as of that date. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 02:01 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 108,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-010168 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,271,166 F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 02:01 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 317,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010168 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,162,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 23:00 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 196,464 | $0.00 Strike: $32.56 | $0.00 |
DisclosureSEC source: 0001127602-21-009570 · form4.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,464 Underlying: Common Shares, No Par Value · 196,464 shares Expires 2031-03-03 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 23:00 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 74,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-009570 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,823 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:47 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 28,192 | $31.42 | $885,792.64 |
DisclosureSEC source: 0001127602-21-009214 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,673 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 5,115 | $15.91 | $81,379.65 |
DisclosureSEC source: 0001127602-20-025186 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,865 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 3,623 | $15.40 | $55,794.20 |
DisclosureSEC source: 0001127602-20-025186 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,980 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:02 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 95,489 | $17.16 | $1,638,591.24 |
DisclosureSEC source: 0001127602-20-015620 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,603 F1 · shares: This number represents common shares, no par value, of the Issuer ("Common Shares") withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 01:03 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 18,488 | $20.96 | $387,508.48 |
DisclosureSEC source: 0001127602-20-010331 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,092 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:28 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 4,925 | $22.52 | $110,911.00 |
DisclosureSEC source: 0001127602-20-009143 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,580 F1 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:28 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 9,269 | $24.44 | $226,534.36 |
DisclosureSEC source: 0001127602-20-009143 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,505 F1 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:33 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 341,114 | $0.00 Strike: $24.77 | $0.00 |
DisclosureSEC source: 0001127602-20-008451 · form4.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,114 Underlying: Common Shares, No Par Value · 341,114 shares Expires 2030-02-26 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:33 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 81,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008451 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 936,774 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 21:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 5,115 | $23.24 | $118,872.60 |
DisclosureSEC source: 0001127602-19-028755 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,734 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 13, 2019 Filed Sep 14, 2019 01:06 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 21,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028360 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860,849 F1 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| September 13, 2019 Filed Sep 14, 2019 01:06 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Shares, No Par Value | 30,000 | $23.31 | $699,300.00 |
DisclosureSEC source: 0001127602-19-028360 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,601 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 20:40 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 18,658 | $23.56 | $439,582.48 |
DisclosureSEC source: 0001127602-19-011053 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,601 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 28, 2019 Filed Feb 28, 2019 21:10 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008918 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747,077 Read SEC document |
| February 28, 2019 Filed Feb 28, 2019 21:10 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Shares, No Par Value | 30,000 | $23.67 | $710,100.00 |
DisclosureSEC source: 0001127602-19-008918 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,077 F1 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:14 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 236,183 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001127602-19-009258 · form4.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,183 Underlying: Common Shares, No Par Value · 236,183 shares Expires 2029-02-27 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:14 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 81,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009258 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,259 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:56 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027734 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,077 F1 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:56 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Shares, No Par Value | 30,000 | $22.32 | $669,600.00 |
DisclosureSEC source: 0001127602-18-027734 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,077 Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:55 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 91,942 | $18.31 | $1,683,458.02 |
DisclosureSEC source: 0001127602-18-016408 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,077 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 13, 2018 Filed Mar 13, 2018 20:38 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | PurchaseCommon Shares, No Par Value | 30,000 | $16.05 | $481,500.00 |
DisclosureSEC source: 0001127602-18-011391 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,019 Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:47 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 511,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011033 · form4.xml · derivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,434 Underlying: Common Stock · 511,434 shares Expires 2021-03-07 F4 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 255,717 and the maximum number that can be distributed is 511,434. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F4 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 255,717 and the maximum number that can be distributed is 511,434. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:47 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 338,058 | $0.00 Strike: $15.32 | $0.00 |
DisclosureSEC source: 0001127602-18-011033 · form4.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,058 Underlying: Common Shares, No Par Value · 338,058 shares Expires 2028-03-07 F3 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:47 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Shares, No Par Value | 113,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011033 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,019 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). F2 · balance_after: Reflects the cancellation, on March 7, 2018, of 933,416 performance-based RSUs granted on May 2, 2016, as reported on a Form 4 filed by the reporting person on May 4, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.